Clinical Study On Sinusitis With Siddha Drug Bhringamala Thailam

Phase II Clinical Study On Sura Peenisam [Sinusitis In Children] With the Evaluation Of the Siddha trial Drug Bhringamala Thailam [Internal]In Children. - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108317

Enrollment

Registered

2026-04-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J019- Acute sinusitis, unspecified

Interventions

Intervention1: Bhringamala Thailam (Internal): Bhringamala Thailam Is Given As Internal Medicine. Dose Is Fixed According to the Pediatric Age and BMI ,bds ,After Food For 15 Days . Control Interventi

Eligibility

Inclusion criteria

Inclusion criteria: Nasal congestion Running nose Headache Heaviness of head Pain and tenderness over PNS Recurrent sneezing

Exclusion criteria

Exclusion criteria: Vasomotor rhinitis Ophthalmic headache Migraine Otitis media Epistaxis

Design outcomes

Primary

Measure	Time frame
Reduction in the SNOT-22 score is assessed by comparing the symptom parameters before and after treatment.Timepoint: 15 days	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr A Satheesh Kumar

Government Siddha Medical College, Arumbakkam, Chennai.

drsatheeshmd@gmail.com9962066694

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026